This website uses cookies to enhance the user experience.
Z

ZYMBIO AS978 677 266

Research
Limited company
Murbræk 7760 SNÅSA, Norge

ZYMBIO AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
27 years
since Jul 7, 1997
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
18,366
1 share class
Total number of shareholders
1
company
Belongs to group of

Financials

Annual total result 2023
-32,146
NOK
Total equity 2023
880,576
NOK
Last update: Sep 11, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO
32 %
indirectly

Board

NameRoleShares
Chairman
32 %
indirectly
Board Member, Contact Person
32 %
indirectly
Alternate Member
12 %
indirectly

Others

NameRoleShares
Accountant-

Top 10 individual shareholders

NameRoleShares
Board Member, Contact Person
32 %
indirectly
Managing Director/CEO, Chairman
32 %
indirectly
-
12 %
indirectly
Alternate Member
12 %
indirectly
-
12 %
indirectly
Last update: Jun 24, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
N
NEUROZYM BIOTECH AS
Ordinary shares
18,366
100 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 0
    Operating profit 2023: NOK -127,152
    Employees: 0

Financials

in NOK

Summary

Year202320222021
Total operating income
0
0
0
Annual Total Result
-32,146
-65,521
-32,119
Total assets
2,277,696
2,306,782
2,370,459
Total liabilities
1,397,120
1,394,060
1,392,215
Total equity
880,576
912,722
978,243

P&L

Year202320222021
Total operating income
0
0
0
Total operating costs
36,074
65,521
36,417
Operating result
-36,074
-65,521
-36,417
Financial income/costs
3,928
0
4,298
Profit before tax
-32,146
-65,521
-32,119
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
-32,146
-65,521
-32,119

Balance overview

Year202320222021
Total fixed assets
2,262,765
15,500
30,550
Total current assets
14,932
2,291,282
2,339,909
Total assets
2,277,696
2,306,782
2,370,459
Short term debt
1,397,120
1,394,060
1,392,215
Long term debt
0
0
0
Total liabilities
1,397,120
1,394,060
1,392,215
Contributed capital
985,575
985,575
985,575
Retained earnings
-104,999
-72,853
-7,332
Total equity
880,576
912,722
978,243
Total equity and liabilities
2,277,696
2,306,782
2,370,459

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology